Wall Street Bullish on Telix Pharmaceuticals (TLX), Here’s Why

​Telix Pharmaceuticals Limited (NASDAQ:TLX) is one of the Best All-Time Low Stocks to Invest In Now. Wall Street is bullish on Telix Pharmaceuticals Limited (NASDAQ:TLX) after the company released its full-year 2025 results on February 19.

​Recently, on February 23, John Hester from Bell Potter reiterated a Buy rating on the stock with a price target of AU$19. On the same day, David Bailey from Morgan Stanley also reiterated a Buy rating on the stock with a price target of AU$25.6.

​In fiscal 2025, the company delivered $803.8 million in revenue, reflecting 56% year-over-year growth and surpassing management’s guidance. Moreover, the company also generated $39.5 million in adjusted EBITDA, despite heavy expenses in strategic acquisitions, investments, and a $157.1 million investment in research and development.

Wall Street Bullish on Telix Pharmaceuticals (TLX), Here's Why

Management attributed growth to its Precision Medicine segment, which increased 22% year-over-year, driven by a continued increase in Illuccix volumes and the successful launch of Gozellix in the US.

​Looking ahead, the company expects fiscal 2026 guidance in the range of $950 million and $970 million. The company also plans to continue spending on R&D, with expenditure expected between $200 million and $240 million.

​Telix Pharmaceuticals Limited (NASDAQ:TLX) is a biopharmaceutical company that specializes in therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. The company is focused on developing clinical and commercial-stage products to address significant unmet medical needs in oncology and rare diseases.

While we acknowledge the potential of TLX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TLX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Follow Insider Monkey on Google News.